|Articles|February 1, 2003

OTCs stem pharm costs, but the jury's still out on long-term savings

The launch of OTC antihistamines helps plans cut costs, but skeptics argue that accessibility will suffer because of cost barriers

Get the latest industry news, event updates, and more from Managed healthcare Executive.

Subscribe Now!

Latest CME

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Tumor Board: Advances in Managing EGFR-Mutant NSCLC—Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Video

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

Jacob Sands, MD; Beth Sandy, MSN, CRNP, FAPO; Stephanie McDonald, FNP-BC, AOCNP

Video

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Mark G. Kris, MD; Justin Gainor, MD; Isabel Preeshagul, DO, MBS; Helena A. Yu, MD

Multimedia

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Jacob Sands, MD; Carl M. Gay, MD, PhD

Multimedia

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Jacob Sands, MD; Martin Wermke, MD

Multimedia

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Jacob Sands, MD; Julia Rotow, MD

Multimedia

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Jacob Sands, MD; Julia Rotow, MD

Multimedia

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

Jacob Sands, MD; Carl M. Gay, MD, PhD

Multimedia

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Benjamin P. Levy, MD; John O. Mascarenhas, MD; Tiffany A. Traina, MD, FASCO; Cathy Eng, MD, FACP, FASCO; John P. Leonard, MD

Multimedia

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

Balazs Halmos, MD, MS; Mark G. Kris, MD; Jamie E. Chaft, MD; Zofia Piotrowska, MD, MHS

Video

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Estelamari Rodriguez, MD, MPH; Millie Das, MD; Ruham Nasany, MD

Video

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

Anne Chiang, MD, PhD; J. Douglas Miles, MD, PhD, FAAN; Suma Satti, MD

Video

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

David R. Gandara, MD; Roy S. Herbst, MD, PhD; Heather A. Wakelee, MD, FASCO

Multimedia

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Zofia Piotrowska, MD, MHS; Bruna Pellini, MD; Alice Shaw, MD, PhD

Video

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Stephen V. Liu, MD; Michelle Afkhami, MD; Ignacio I. Wistuba, MD; Helena Yu, MD

Video

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Marina Chiara Garassino, MD; Sarah Goldberg, MD, MPH; Biagio Ricciuti, MD, PhD

Video

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

Jacob Sands, MD; Anne Chiang, MD, PhD; Alissa J. Cooper, MD

Video

22nd Annual Winter Lung Cancer Conference®

Julie Brahmer, MD; Rogerio C. Lilenbaum, MD, FACP, FASCO; Mark A. Socinski, MD

Video

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Audio

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Fred Hirsch, MD, PhD, FASCO; Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO

Video

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Lauren Averett Byers, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS

Video

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Benjamin P. Levy, MD; Ticiana Leal, MD; Aaron Lisberg, MD; Christine M. Lovly, MD, PhD, FASCO

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Jacob Sands, MD; Jennifer Carlisle, MD; Hossein Borghaei, DO, MS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Multimedia

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

Jonathan Goldman, MD; Erminia Massarelli, MD, PhD, MS; Jorge J. Nieva, MD; Ignacio I. Wistuba, MD

Video

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Sandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHS

Video

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

Tina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhD

Video

26th Annual International Lung Cancer Congress

Roy S. Herbst, MD, PhD; Sandip Patel, MD, FASCO; Heather A. Wakelee, MD, FASCO

Video

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

Anne Chiang, MD, PhD; Erminia Massarelli, MD, PhD, MS; Zofia Piotrowska, MD, MHS

In-Person Event

2nd Annual Hawaii Cancer Conference

January 24-25, 2026

In-Person Event

23rd Annual Winter Lung Cancer Conference®

January 23-25, 2026

Video

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Megan E. Daly, MD; Nagla F. Abdel Karim, MD, PhD; Chul Kim, MD

Video

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

Megan E. Daly, MD; Nagla F. Abdel Karim, MD, PhD; Chul Kim, MD

Video

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

Percy Lee, MD, FASTRO; David Harpole Jr, MD; Julia Rotow, MD

Video

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

Percy Lee, MD, FASTRO; David Harpole Jr, MD; Julia Rotow, MD

In-Person Event

27th Annual International Lung Cancer Congress®

July 25-26, 2026

Video

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Charu Aggarwal, MD, MPH, FASCO; Christine Bestvina, MD; Hatim Husain, MD; Karen L. Reckamp, MD, MS

In-Person + Virtual Event

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

October 26, 2025

In-Person + Virtual Event

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

December 5, 2025

In-Person Event

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

January 22, 2026

In-Person Event

20th Annual New York Lung Cancers Symposium®

November 15, 2025

OTCs stem pharm costs, but the jury's still out on long-term savings

Newsletter

Related Content

A Conversation With IQVIA's Luke Greenwalt, MBA

Doug Long on the Changes He Has Seen and Retirement | PBMI 2024

Doug Long on the State of U.S. Healthcare, Pharmacy Deserts and "Pretty Anemic" Number of Drug Launches | PBMI 2024

The Whys of Disrupting the Specialty Pharmacy Marketplace | PBMI 2024

A Conversation With Greg Baker, RPh, CEO of AffirmedRx

Latest CME

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Tumor Board: Advances in Managing EGFR-Mutant NSCLC—Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

Virtual Tumor Board for the Onco-Nurse: Improving Outcomes in SCLC Treatment and AE Management

Cases & Conversations™: Integrating Novel Approaches to Treatment in First-line ALK+ mNSCLC – Enhancing Patient Outcomes with Real World Multidisciplinary Strategies

Burst CME™: Exploring Diagnosis and Testing Innovations for Targetable Mutations in SCLC

Burst CME™: Addressing Diagnostic Challenges and Identifying Targets for Treatment in LCNEC-L

Burst CME™: Advanced Diagnostic and Testing Approaches for Mutation-Targetable Management of NSCLC

Burst CME™: The Role of HER2 in NSCLC and Implications for Emerging Treatment Strategies

Future Directions in Treating SCLC and LCNEC-L: The Impact of DLL3

42nd Annual CFS: Chemotherapy Foundation Symposium®: Innovative Cancer Therapy for Tomorrow

Community Practice Connections™: 19th Annual New York Lung Cancers Symposium®

A Breath of Strength: Managing Cancer Associated LEMS and Lung Cancer as One

Striking the Right Nerve: Managing Cancer Associated LEMS in Lung Cancer Patients

3rd Annual Hawaii Lung: A Multidisciplinary Case-Based Conference

Community Practice Connections™: Incorporating Recent Updates in the Treatment of Metastatic ALK-Positive NSCLC

Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

22nd Annual Winter Lung Cancer Conference®

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: DLL3-Driven Innovations in Small Cell Lung Cancer – How Do Experts Apply Pivotal Advances to Practice?

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Community Practice Connections™: Distinguishing Precision Pathways for c-Met and MET Alterations in NSCLC

A New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCs

Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease Continuum

26th Annual International Lung Cancer Congress

Transforming Treatment in Small Cell Lung Cancer: How Recent Trials Are Shaping Treatment Decision-Making and Future Therapies

2nd Annual Hawaii Cancer Conference

23rd Annual Winter Lung Cancer Conference®

(MOC and CME Credit) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

(CME Credit Only) New Frontiers in Immunotherapy for SCLC: Insights From Latest Clinical Trials and Their Application in Real-World Treatment

(MOC and CME Credit) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

(CME Credit Only) Lung Cancer Tumor Board®: The Pivotal Role of Multimodal Therapy in Leveraging Immunotherapy for Stage I-III NSCLC When the Goal Is Cure

27th Annual International Lung Cancer Congress®

Lung Cancer Tumor Board: Enhancing Precision Medicine in NSCLC Through Advancements in Molecular Testing and Optimal Therapy Selection

Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient Outcomes

From Clue to Care: Rapid Recognition and Coordinated Management of Paraneoplastic LEMS in SCLC

Inaugural Brain & Spine Metastases Conference: Evolving Practice and Emerging Therapies

20th Annual New York Lung Cancers Symposium®

Trending on Managed Healthcare Executive

Sponsored: The Teva Biosimilars Trend Report

Medicaid Unwinding Drops Coverage for Millions but Uninsured Rate Remains Steady

FDA Accepts NDA for Investigational Maintenance Asthma Treatment

The 6-Year Cure Threshold: Redefining Cure for Colon Cancer Survivors

AI Crucial Tool for Patient Management, Lowering Readmission Risk, Expert Says